Regeneron's Trading Volume Surges to $14.78 Billion, Ranked 27th in Market

On April 29, 2025, Regeneron's trading volume reached $14.78 billion, marking a significant increase of 106.65% from the previous day, placing it at the 27th position in the day's stock market rankings. Regeneron's stock price fell by 6.87%.

Regeneron Pharmaceuticals, Inc. (REGN) has announced that its board of directors has declared a quarterly dividend of $1.15 per share on the company's common stock. The dividend is payable on June 14, 2025, to stockholders of record at the close of business on May 31, 2025. This dividend reflects the company's strong financial performance and commitment to returning value to its shareholders.

Regeneron has also reported positive results from its Phase 3 clinical trial for a new drug candidate aimed at treating a rare genetic disorder. The trial met its primary endpoint, demonstrating a statistically significant improvement in patients' symptoms compared to the placebo group. This success highlights the company's continued innovation in the biopharmaceutical sector and its potential to bring new treatments to patients in need.

Additionally, Regeneron has entered into a strategic collaboration with a leading academic institution to advance research in the field of immunology. This partnership aims to leverage the strengths of both organizations to develop novel therapies for autoimmune diseases, further solidifying Regeneron's position as a leader in the biotechnology industry.